What Are The Strategic Insights Behind The Adeno-Associated Viral Vectors Market Expansion To $5.85 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Adeno-Associated Viral Vectors Market Size?
The market size for adeno-associated viral vectors has witnessed swift expansion recently. The market value, which stood at $2.69 billion in 2024, is projected to expand to $3.17 billion in 2025, recording a compound annual growth rate (CAGR) of 17.6%. The growth during the historical period can be ascribed to factors such as vaccine development, higher fund allocation and investment, collaborations between academia and industry, advancement of clinical trials, and amplified public awareness and support.
The market size of adeno-associated viral vectors is projected to experience accelerated expansion in the coming years, reaching $5.85 billion by 2029 with a compound annual growth rate (CAGR) of 16.6%. The expected growth during the forecast period could be due to increased therapeutic applications, a rising number of genetic and neurological disorders, regulatory endorsements and support, and decreased production costs. Predominant trends for the forecast period encompass advancements in gene therapy, cutting-edge technology, scalable manufacturing procedures, joint ventures and investments, along with technological progress.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp
Which Demand Drivers Are Strengthening The Adeno-Associated Viral Vectors Market?
The rising instances of genetic disorders are anticipated to fuel the expansion of the adeno-associated viral vectors market. Genetic disorders, which are health conditions resulting from DNA abnormalities, can cause physical or developmental issues. Factors such as improved diagnostic methods, broadened awareness, demographic shifts to higher reproductive age, as well as environmental elements and genetic drift, are all contributing to the escalating prevalence of these disorders. Adeno-associated viral vectors come into play here as they are used in gene therapy for these disorders, administering restorative genes to targeted cells which could potentially address diseases like muscular dystrophy or cystic fibrosis. For instance, data from the World Health Organization (WHO), a Switzerland-based specialized arm of the United Nations in charge of international public health, reported in February 2023 that around 240,000 neonatal deaths worldwide annually occur due to congenital diseases within the first 28 days after birth. Besides, congenital diseases claim an additional 170,000 children aged between 1 month and 5 years. Hence, the escalating frequency of genetic disorders is a significant driving factor for the adeno-associated viral vectors market.
What Segmentation Insights Are Provided In The Adeno-Associated Viral Vectors Market Research?
The adeno-associated viral vectorsmarket covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation; Immunotherapy; Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo; In Vivo
3) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical; Clinical; Commercial
5) By Application Area: Gene Therapy; Cell Therapy; Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders; Muscular Dystrophy; Cystic Fibrosis; Hemophilia
2) By Immunotherapy: Cancer Immunotherapy; Viral Infections Immunotherapy; Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing; RNA Therapy; Antiviral Therapy
Which Notable Trends Are Transforming The Adeno-Associated Viral Vectors Market Outlook?
Major corporations in the adeno-associated viral vectors sector are aiming to gain a competitive advantage by providing readily available replication-capsid plasmid. This molecule, frequently used in the creation of gene therapy vectors for adeno-associated viruses (AAV), is easily accessible through various commercial vendors serving molecular biology study needs. For instance, Charles River Laboratories International Inc, a pharmaceutical firm in the US, launched a readily available replication-capsid plasmid range in January 2024 to smoothen AAV-focused gene therapy endeavors. The company’s expanded product range complements its current offerings of lentiviral packaging and AAV Helper plasmids, reducing manufacturing efforts by up to 66%. These ready-to-inject plasmids are produced in batches, with stringent documentation following CMC guidelines, and include a Certificate of Analysis (COA) to simplify IND and Clinical Trial Application (CTA) procedures.
Which Firms Are Driving Innovation Within The Adeno-Associated Viral Vectors Market?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics
Access The Complete Report Here:
Which Regional Markets Are Emerging As Key Hubs For The Adeno-Associated Viral Vectors Market?
North America was the largest region in the adeno-associated viral vectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp
Browse Through More Reports Similar to the Global Adeno-Associated Viral Vectors Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Bacterial And Plasmid Vector Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report
Adenosine Triphosphate Atp Assays Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
